Dr. Desirée Cox Appointed to Hemostemix’ Board of Directors

Calgary, Alberta, May 25, 2026: Hemostemix Inc. (TSXV: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous stem cell company offering treatment to those who suffer from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, in The Bahamas, is pleased to announce the appointment of Dr. Desirée Cox to its Board of Directors.

Dr. Cox joins Hemostemix at a pivotal time as the Company is commercializing ACP-01 (VesCell™) in The Bahamas, completing a commercial Phase I clinical trial using a basket protocol approach.

“Dr. Cox brings a rare combination of scientific rigor, philosophical depth, ethical leadership, and global health policy experience,” said Thomas Smeenk, President and CEO of Hemostemix. “Her work at the intersection of medicine, ethics, regenerative medicine, and public policy has shaped The Bahamas into one of the world’s leading jurisdictions for ethically approved regenerative medicine innovation. Her appointment strengthens Hemostemix’s commitment to scientific excellence, ethical governance, commercialization and global leadership in regenerative medicine.”

Dr. Cox stated:

“Hemostemix’s ACP-01 platform represents a compelling convergence of regenerative medicine, vascular biology, and patient-centered innovation. I believe regenerative medicine will fundamentally reshape healthcare over the next several decades, and I look forward to supporting Hemostemix as it advances therapies aimed at restoring microvascular function, improving quality of life, and expanding responsible access to novel treatments.”

About Dr. Desirée Cox

Dr. Desirée Cox (MD, MPhil, PhD) is a physician, scientist, philosopher, bioethicist, quantum chemist, and artist whose work spans medicine, ethics, public policy, regenerative medicine, and human flourishing.

The first-born child of a barber and a secretary, Dr. Cox was raised with an unwavering belief in education and scholarship. Her mother enrolled her in a private school that consumed nearly two-thirds of the family income, telling the five-year-old Dr. Cox that she would one day attend university and must earn scholarships through discipline and academic excellence. At age fifteen, after reading a brochure describing University of Oxford as a place where the world’s leading intellectuals created new knowledge, she envisioned herself studying there and contributing globally to medicine and healthcare. Despite being ridiculed by peers for her ambitions, she pursued that vision relentlessly.

Dr. Cox, a Rhodes Scholar, earned academic and professional distinctions from several of the world’s leading institutions, including McGill University (BSc), University of Oxford (MD, Rhodes Scholar), and University of Cambridge (MPhil, PhD). Dr. Cox has served as a leader in regenerative medicine ethics and governance in The Bahamas for more than a decade.

She previously chaired the National Stem Cell Ethics Committee in The Bahamas and spearheaded the development of the ethical and legislative framework underpinning the country’s Longevity and Regenerative Therapies Act (“LARTA”), legislation designed to establish The Bahamas as a global center for regenerative medicine, longevity sciences, and responsible clinical innovation.

Dr. Cox is the founder of HEALinc, a global health innovation platform for the restoration of whole-person health and affordable global access to regenerative advanced longevity-enhancing lifestyle technologies, products and services.

Her appointment reflects Hemostemix’s strategy of focusing on assembling globally recognized scientific, ethical, and regenerative medicine policy focused leadership, as the Company advances ACP-01 as a treatment in The Bahamas and internationally.

About Hemostemix

Hemostemix Inc. is an autologous stem cell therapy company focused on the development and commercialization of ACP-01 (VesCell™), a patient-derived angiogenic cell precursor therapy designed to regenerate microcirculation in patients with ischemic and degenerative diseases. Hemostemix has published clinical research demonstrating safety and preliminary efficacy across cardiovascular and vascular indications, including chronic limb threatening ischemia, peripheral arterial disease, ischemic cardiomyopathy, dilated cardiomyopathy, and chronic stable angina.

For more information, please visit: Hemostemix Inc.

ON BEHALF OF THE BOARD OF DIRECTORS

Thomas Smeenk
President, CEO and Director
Hemostemix Inc.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the appointment of Dr. Desiree Cox as a Director of Hemostemix Inc., and the treatment of conditions of ischemia in The Bahamas with Angiogenic Cell Precursors (ACP-01), in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of treatments in The Bahamas. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the “Litigation”), if any; the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.